SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680687.
  • 2
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673684.
  • 3
    Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250256.
  • 4
    Berenguer M, Prieto M, Rayon J, Mora J, Pastro M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852858.
  • 5
    European Liver Transplant Registry (ELTR). Registry for the European Liver Transplant Association. Available at: http://www.eltr.org.
  • 6
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucy MR. Association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 7
    Wiesner R H, Sorrell M, Villamil F, the International Liver Transplantation Society Expert Panel. Liver Transpl 2003; 9: S1S9.
  • 8
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 15131520.
  • 9
    Wiesner RH, Sorrell M, Villamil F, the International Liver Transplantation Society Expert Panel. Report of the first International liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 11: S1S9.
  • 10
    Samuel D. Antiviral treatment of recurrent hepatitis C after live transplantation: he need for a multifaceted approach. Hepatology 2005; 41: 436438.
  • 11
    Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol 2004; 41: 210.
  • 12
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 13
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marios G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 14
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669674.
  • 15
    Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α 2b and ribavirin: an open-label series. Transplantation 2004; 77: 190194.
  • 16
    Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 30423044.
  • 17
    Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 18
    Bizollon T, Ahmed SNS, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283287.
  • 19
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199207.
  • 20
    Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22: 1084.
  • 21
    Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500504.
  • 22
    Götz G, Schön MR, Haefker A, Neuhaus T, Berg T, Hopt U, et al. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc 1998: 30: 21042106.
  • 23
    De Vera ME, Smallwood GA, Rosado K, Davis L, Martinez E, Sharma S, et al. Interferon-α and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678686.
  • 24
    Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 7: 870876.
  • 25
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a nonrandomised trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7: 863869.
  • 26
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 10001006.
  • 27
    Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 12531258.
  • 28
    Samuel D, Bizollon T, Feray C, Roche B, Si Ahmed SN, Lemonnier C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642650.
  • 29
    Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289298.
  • 30
    Cotler SJ, Taylor SL, Gretch DR, Bronner MP, Rizk R, Perkins JD, et al. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients. Am J Gastroenterol 2000; 95: 753759.
    Direct Link:
  • 31
    Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 11781182.